Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02593045 · ClinicalTrials.gov registry record · Phase 1
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
A Phase 1 study, sponsored by Innate Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT02593045 is a Phase 1 study that has completed, run by Innate Pharma. The registered enrollment target is 44 participants.
The verdict
NCT02593045, a Phase 1 study, has completed, sponsored by Innate Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the dose limiting toxicities (DLT) and identify a Maximum Tolerated Dose (MTD).
Interventions
- BIOLOGICAL IPH4102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-10 |
| Est. Completion | 2020-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02593045
The ClinicalTrials.gov registry entry for NCT02593045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innate Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPH4102 is the first listed.
NCT02593045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02593045 about?
NCT02593045 is a clinical study titled "Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)". The primary objective of this first in human study is to assess the safety and tolerability of increasing intravenous (IV) doses of single agent IPH4102 administered to patients with relapsed/refractory CTCL to characterize the dose limiting toxicities (DLT) and identify a Maximum Tolerated Dose (MT...
What is the current status of trial NCT02593045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2015-10. Estimated completion is 2020-04.
What interventions are being tested in trial NCT02593045?
The interventions under investigation include: IPH4102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02593045?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.